Home
Resources
Follow portfolio news
...

Democratizing DNA sequencing: Ultima Genomics joins forces with Gene by Gene

Published on
8/10/2025
Amended on
25/3/2026
0
minute(s)
Odyssey 2021
Ultima Genomics
Ultima Genomics has established itself as a key player in the field of genomics thanks to its platform, which enables large-scale DNA sequencing with unprecedented accuracy and speed. The company, which is part of the Vintage FPCI Altaroc Odyssey portfolio, has just announced a partnership with Gene by Gene, a global leader in genetic testing.
By
Antoine Orsoni
Antoine Orsoni
Democratizing DNA sequencing: Ultima Genomics joins forces with Gene by Gene
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
This article has been automatically translated. We apologize per inaccuracies or translation errors.

Gene by Gene becomes one ofUltima Genomics' Certified Service Providers, alongside the University of Minnesota Genome Center and the New York Genome Center. Gene by Gene will thus be able to offer its customers all over the world, such as the University of Glasgow or the MD Anderson Center in Texas, full genome sequencing (reading and decoding a person's entire DNA), as well as numerous other applications based on the Ultima Genomics platform.

Thanks to Ultima Genomics' technology, it is now possible to obtain genetic analyses of exceptional quality, while considerably reducing costs. This democratization of sequencing opens the way to major applications ranging from medical diagnosis and scientific research to consumer testing and forensic investigations. Ultima Genomics has already assisted and supported several renowned institutions, including Broad Clinical Labs and the Ontario Institute for Cancer Research. This network illustrates the company's ambition: to give everyone, researchers and doctors alike, access to a high-performance, affordable sequencing tool. Ultima Genomics has also been commissioned to carry out the largest-ever study of human proteins.

This momentum is underpinned by constant innovation, notably the recent introduction of Solaris chemistry, which, combined with high-performance software and streamlined processes, has increased the sequencing capacity of the Ultima Genomics platform by over 50%. In concrete terms, each cycle can now generate up to 12 billion DNA reads, driving down costs even further, while speeding up the work of scientific teams. Solaris chemistry also enables an even greater reduction in costs, of around 20% per read, as well as greater precision, now making it possible to work with even smaller quantities of DNA (between 50 and 100 times less).

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
No items found.
North America
Healthcare
Welcome to Altaroc
To provide you with a tailored experience, please complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
YOUR INVESTOR PROFILE
Financial intermediary or professional investor
Financial advisors, wealth managers, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced investor or Altaroc investor
Private investors who have already invested with Altaroc or who have a minimum investment capacity of €100,000.
Private investors who have previously invested in Altaroc who have a minimum investment capacity of 200,000 euros.
Non-professional (retail) investor
Individual investors with an investment capacity below €100,000.
Retail investors with an investment capacity of less than 200,000 euros.
Institutional investor
Pension funds, retirement schemes, asset management companies, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.